



Innovator & Sustainable Environmental Solutions Provider

Stock Symbol: BLGO

Westminster, CA

Safe Harbor Statement

The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo's current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo's Annual Report on Form 10-K. This presentation includes estimates of market size, revenue per client site and revenue based upon customer adoption rates. All such statements are forward-looking statements and, although based upon assumptions the Company believes to be reasonable, are not projections of actual revenue or earnings which may be substantially less. There can be no guaranty that any national account customer adopts the use of our products and we cannot predict the adoption rate, if any, by our customers and potential customers. Revenue per customer site may be affected by many factors, including but not limited due to distribution, price competition, fluctuating supplier pricing, size, population density, location and weather.


BioLargo Solves Tough Problems with Top Technologies




Environmental Group



Medical Division
(minority interest + IP license/royalty)




IP Portfolio



Revenues climbing, debt decreasing


Quarterly Revenue

Q4 = projected¹



- All BioLargo
- BioLargo without Clyra
- Clyra


Debt²



- All BioLargo
- BioLargo without Clyra
- Clyra

¹Additional \$130K in ONM-E sales secured, will book as revenue in Q1 2021.
²1,085,000 in debt due in August 2021, with the remaining to be paid by Clyra subsidiary from sales or as funds are available from financing efforts

New Sources of Revenue Converging



**Positive
cash flow
on horizon**

2014

2015

2016

2017

2018

2019

2020

2021



New deployment systems
increase sales scalability
+ EPA



Contract in place – first
customer \$500K



Clyraguard launched and new
products to launch in 2021



= first sales / expected first sales



Engineers – current backlog
+\$1.6M
First AEC commercial pilots
targeting Q1

Industrial air quality control solutions






BioLargo Engineering Solutions

Citizens Gas
Union Carbide
HAVCO
DOD
TSCAI
DOE
ENREMA
Proton Power
USAF
Schlegel
Moss Landing
US Army
Picatinny Arsenal
Oak Ridge National Lab
Major Waste Handlers
Lamb Weston




PFAS Treatment Technology reading for commercial trials






**Low cost – Energy Efficient – Extreme
Performance – Micropollutant removal**



**First unit for Montreal pilot
preparing to ship**



FIRST COMMERCIAL TRIALS AND PROJECTS



Expanding Product Line of Medical Products



Surgical Irrigation



Dental Hygiene



Chronic Wound Care



SkinDisc Stem Cell Therapy

FDA 510(k) cleared for first product fall 2019

Clyraguard™

**DISINFECTING
PERSONAL PROTECTION
SPRAY**



**Extremely High
Antimicrobial Efficacy**
99.999% Effective* *against virus, bacteria and fungi*

Proven effective against SARS-CoV-2, the virus that causes COVID-19*

Skin friendly, non-irritating, non-toxic, non-sensitizing.

*data/references on file (including SARS-CoV-2 virus testing)
*<https://1000research.com/articles/9-674>

Stock Symbol: BLGO

Contact:

Dennis Calvert
President & CEO
BioLargo, Inc.
14921 Chestnut St.
Westminster, CA 92683
(888) 400-2863
dc@BioLargo.com
www.BioLargo.com

The BioLargo Family of Companies

BioLargo, Inc. is a sustainable science, technology & full-service environmental engineering company that **makes life better** by delivering world-class products and services across a broad range of industries, with a drive to deliver clean water, clean air, and advanced antimicrobials for healthcare.

